vs
Side-by-side financial comparison of Biogen (BIIB) and Fidelity National Information Services (FIS). Click either name above to swap in a different company.
Fidelity National Information Services is the larger business by last-quarter revenue ($2.8B vs $2.3B, roughly 1.2× Biogen). Fidelity National Information Services runs the higher net margin — 18.2% vs -2.1%, a 20.3% gap on every dollar of revenue. On growth, Fidelity National Information Services posted the faster year-over-year revenue change (8.1% vs -7.1%). Fidelity National Information Services produced more free cash flow last quarter ($739.0M vs $468.0M). Over the past eight quarters, Fidelity National Information Services's revenue compounded faster (6.8% CAGR vs -0.2%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Fidelity National Information Services, Inc. (FIS) is an American multinational corporation which offers a wide range of financial products and services. FIS is most known for its development of Financial Technology, or FinTech. Annually, FIS facilitates the movement of roughly US$9 trillion through the processing of approximately 75 billion transactions in service to more than 20,000 clients around the globe.
BIIB vs FIS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $2.8B |
| Net Profit | $-48.9M | $511.0M |
| Gross Margin | 78.3% | 38.3% |
| Operating Margin | -2.5% | 18.8% |
| Net Margin | -2.1% | 18.2% |
| Revenue YoY | -7.1% | 8.1% |
| Net Profit YoY | -118.3% | 97.3% |
| EPS (diluted) | $-0.35 | $0.98 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3B | $2.8B | ||
| Q3 25 | $2.5B | $2.7B | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $2.4B | $2.5B | ||
| Q4 24 | $2.5B | $2.6B | ||
| Q3 24 | $2.5B | $2.6B | ||
| Q2 24 | $2.5B | $2.5B | ||
| Q1 24 | $2.3B | $2.5B |
| Q4 25 | $-48.9M | $511.0M | ||
| Q3 25 | $466.5M | $264.0M | ||
| Q2 25 | $634.8M | $-470.0M | ||
| Q1 25 | $240.5M | $77.0M | ||
| Q4 24 | $266.7M | $259.0M | ||
| Q3 24 | $388.5M | $224.0M | ||
| Q2 24 | $583.6M | $243.0M | ||
| Q1 24 | $393.4M | $724.0M |
| Q4 25 | 78.3% | 38.3% | ||
| Q3 25 | 73.4% | 37.8% | ||
| Q2 25 | 77.1% | 36.4% | ||
| Q1 25 | 74.1% | 34.7% | ||
| Q4 24 | 76.2% | 36.9% | ||
| Q3 24 | 74.1% | 38.0% | ||
| Q2 24 | 77.8% | 38.2% | ||
| Q1 24 | 76.3% | 37.1% |
| Q4 25 | -2.5% | 18.8% | ||
| Q3 25 | 22.0% | 16.8% | ||
| Q2 25 | 28.1% | 15.6% | ||
| Q1 25 | 12.8% | 13.7% | ||
| Q4 24 | 11.9% | 18.5% | ||
| Q3 24 | 18.3% | 19.1% | ||
| Q2 24 | 28.3% | 15.2% | ||
| Q1 24 | 20.3% | 14.6% |
| Q4 25 | -2.1% | 18.2% | ||
| Q3 25 | 18.4% | 9.7% | ||
| Q2 25 | 24.0% | -18.0% | ||
| Q1 25 | 9.9% | 3.0% | ||
| Q4 24 | 10.9% | 10.0% | ||
| Q3 24 | 15.8% | 8.7% | ||
| Q2 24 | 23.7% | 9.8% | ||
| Q1 24 | 17.2% | 29.3% |
| Q4 25 | $-0.35 | $0.98 | ||
| Q3 25 | $3.17 | $0.50 | ||
| Q2 25 | $4.33 | $-0.90 | ||
| Q1 25 | $1.64 | $0.15 | ||
| Q4 24 | $1.82 | $0.51 | ||
| Q3 24 | $2.66 | $0.41 | ||
| Q2 24 | $4.00 | $0.44 | ||
| Q1 24 | $2.70 | $1.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $599.0M |
| Total DebtLower is stronger | $6.3B | $9.1B |
| Stockholders' EquityBook value | $18.3B | $13.9B |
| Total Assets | $29.4B | $33.5B |
| Debt / EquityLower = less leverage | 0.34× | 0.65× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $599.0M | ||
| Q3 25 | — | $571.0M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | — | $805.0M | ||
| Q4 24 | — | $834.0M | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $3.3B |
| Q4 25 | $6.3B | $9.1B | ||
| Q3 25 | $6.3B | $8.9B | ||
| Q2 25 | $6.3B | $8.9B | ||
| Q1 25 | $4.5B | $8.7B | ||
| Q4 24 | $6.3B | $9.7B | ||
| Q3 24 | $4.5B | $10.5B | ||
| Q2 24 | $6.3B | $10.6B | ||
| Q1 24 | $6.3B | $10.6B |
| Q4 25 | $18.3B | $13.9B | ||
| Q3 25 | $18.2B | $13.9B | ||
| Q2 25 | $17.6B | $14.2B | ||
| Q1 25 | $17.0B | $15.1B | ||
| Q4 24 | $16.7B | $15.7B | ||
| Q3 24 | $16.4B | $16.6B | ||
| Q2 24 | $15.9B | $17.0B | ||
| Q1 24 | $15.2B | $18.0B |
| Q4 25 | $29.4B | $33.5B | ||
| Q3 25 | $29.2B | $33.0B | ||
| Q2 25 | $28.3B | $33.4B | ||
| Q1 25 | $28.0B | $32.8B | ||
| Q4 24 | $28.0B | $33.8B | ||
| Q3 24 | $28.3B | $34.3B | ||
| Q2 24 | $26.8B | $34.6B | ||
| Q1 24 | $26.6B | $35.9B |
| Q4 25 | 0.34× | 0.65× | ||
| Q3 25 | 0.35× | 0.64× | ||
| Q2 25 | 0.36× | 0.63× | ||
| Q1 25 | 0.27× | 0.57× | ||
| Q4 24 | 0.38× | 0.62× | ||
| Q3 24 | 0.28× | 0.63× | ||
| Q2 24 | 0.40× | 0.62× | ||
| Q1 24 | 0.41× | 0.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $511.9M | $758.0M |
| Free Cash FlowOCF − Capex | $468.0M | $739.0M |
| FCF MarginFCF / Revenue | 20.5% | 26.3% |
| Capex IntensityCapex / Revenue | 1.9% | 0.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1B | $2.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $511.9M | $758.0M | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $160.9M | $382.0M | ||
| Q1 25 | $259.3M | $457.0M | ||
| Q4 24 | $760.9M | $782.0M | ||
| Q3 24 | $935.6M | $641.0M | ||
| Q2 24 | $625.8M | $546.0M | ||
| Q1 24 | $553.2M | $206.0M |
| Q4 25 | $468.0M | $739.0M | ||
| Q3 25 | $1.2B | $952.0M | ||
| Q2 25 | $134.3M | $343.0M | ||
| Q1 25 | $222.2M | $420.0M | ||
| Q4 24 | $721.6M | $764.0M | ||
| Q3 24 | $900.6M | $605.0M | ||
| Q2 24 | $592.3M | $530.0M | ||
| Q1 24 | $507.3M | $179.0M |
| Q4 25 | 20.5% | 26.3% | ||
| Q3 25 | 48.4% | 35.0% | ||
| Q2 25 | 5.1% | 13.1% | ||
| Q1 25 | 9.1% | 16.6% | ||
| Q4 24 | 29.4% | 29.4% | ||
| Q3 24 | 36.5% | 23.5% | ||
| Q2 24 | 24.0% | 21.3% | ||
| Q1 24 | 22.1% | 7.3% |
| Q4 25 | 1.9% | 0.7% | ||
| Q3 25 | 1.8% | 2.2% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 1.5% | 1.5% | ||
| Q4 24 | 1.6% | 0.7% | ||
| Q3 24 | 1.4% | 1.4% | ||
| Q2 24 | 1.4% | 0.6% | ||
| Q1 24 | 2.0% | 1.1% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 2.73× | 3.83× | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | 5.94× | ||
| Q4 24 | 2.85× | 3.02× | ||
| Q3 24 | 2.41× | 2.86× | ||
| Q2 24 | 1.07× | 2.25× | ||
| Q1 24 | 1.41× | 0.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
FIS
| Banking Solutions | $1.6B | 57% |
| Other | $701.0M | 25% |
| Capital Market Solutions | $508.0M | 18% |
